DelveInsight’s “Friedreich’s Ataxia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Friedreich’s Ataxia, historical and forecasted epidemiology as well as the Friedreich’s Ataxia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Friedreich’s Ataxia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Friedreich’s Ataxia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Friedreich’s Ataxia Market Insights
Some of the key facts of the Friedreich’s Ataxia Market Report:
- The Friedreich’s Ataxia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
- In February 2024, Biogen’s SKYCLARYS (omaveloxolone) has been approved by the European Commission for treating Friedreich’s Ataxia in individuals aged 16 years and above.
- In February 2024, Larimar Therapeutics, headquartered in the United States, has released encouraging top-line findings from a Phase II exploratory study of the Friedreich’s ataxia treatment, nomlabofusp (CTI-1601). CEO Dr. Carole Ben-Maimon has expressed intentions to initiate a confirmatory trial for the medication, with plans to submit a biologics license application (BLA) to the US Food and Drug Administration (FDA) in the second half of 2025.
- In September 2023, Vatiquinone (PTC-743), previously recognized as EPI-743, is an experimental oral therapy aimed at mitigating neuroinflammation and nerve cell deterioration in individuals with Friedreich’s ataxia (FA). This treatment has been granted orphan drug and fast track designations by the U.S. Food and Drug Administration for FA treatment, alongside orphan drug status in the European Union. These designations are intended to expedite clinical progress. PTC Therapeutics is spearheading its development after its acquisition from BioElectronTechnology Corporation in 2019. Moreover, investigations are underway to explore its efficacy in managing seizures among individuals with mitochondrial diseases.
- In February 2023, The US FDA has granted approval to Reata Pharmaceuticals’ omaveloxolone, marketed as SKYCLARYS, for treating Friedreich’s Ataxia in individuals aged 16 years and older.
- As per the statistics by National Institute of Neurological Disorders and Stroke, although rare, FA is the most common form of hereditary ataxia in the United States, affecting about 1 in every 50,000 people. Adult or late-onset FA is less common, <25% of diagnosed individuals, and can occur anytime during adulthood
- In a study by Delatycki et al., the availability of molecular diagnosis, FA was estimated to affect about 1/50,000 people with an estimated carrier prevalence of about 1/110. However, recent studies based on molecular data suggest a higher prevalence
- Key Friedreich’s Ataxia Companies: Reata Pharmaceuticals, Retrotope, PTC Therapeutics, Minoryx Therapeutics, and others
- Key Friedreich’s Ataxia Therapies: Omaveloxolone, RT001, Vatiquinone, Leriglitazone, and others
- The Friedreich’s Ataxia epidemiology based on gender analyzed that males and females are equally affected by Friedreich’s Ataxia
Get a Free sample for the Friedreich’s Ataxia Market Report:
https://www.delveinsight.com/report-store/friedreichs-ataxia-market
Friedreich’s Ataxia Overview
Friedreich’s ataxia (FA) is a rare, inherited neurological disorder characterized by progressive damage to the nervous system. It primarily affects the spinal cord and the cerebellum, which is the part of the brain responsible for coordinating movement. FA typically manifests during childhood or adolescence and can lead to symptoms such as difficulty walking (ataxia), loss of coordination and balance, muscle weakness, speech problems, vision and hearing impairment, and in some cases, heart complications.
Friedreich’s Ataxia Market
The dynamics of the Friedreich’s Ataxia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
“Heart failure can develop in Friedreich’s Ataxia patients with marked hypertrophy and may be associated with preserved ejection fraction. In later stages of FA heart disease the ventricles may dilate and ejection fraction falls.”
Friedreich’s Ataxia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Friedreich’s Ataxia Epidemiology Segmentation:
The Friedreich’s Ataxia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Total Prevalence of Friedreich’s Ataxia
- Prevalent Cases of Friedreich’s Ataxia by severity
- Gender-specific Prevalence of Friedreich’s Ataxia
- Diagnosed Cases of Episodic and Chronic Friedreich’s Ataxia
Download the report to understand which factors are driving Friedreich’s Ataxia epidemiology trends @ Friedreich’s Ataxia Epidemiological Insights
Friedreich’s Ataxia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Friedreich’s Ataxia market or expected to get launched during the study period. The analysis covers Friedreich’s Ataxia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers Friedreich’s Ataxia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
To know more about Friedreich’s Ataxia treatment, visit @ Friedreich’s Ataxia Medications
Friedreich’s Ataxia Therapies and Key Companies
- Omaveloxolone: Reata Pharmaceuticals
- RT001: Retrotope
- Vatiquinone: PTC Therapeutics
- Leriglitazone: Minoryx Therapeutics
Friedreich’s Ataxia Market Drivers
- Friedreich’s Ataxia is a complex disorder, efforts have been made by researchers and scientific professionals to improve the understanding of the pathogenesis and diagnosis of this condition
- Treatment of Friedreich’s Ataxia has improved significantly in recent years with the availability of several safe and effective therapies. Several consensus guidelines have been created to further assist in the management of Friedreich’s Ataxia patients
Friedreich’s Ataxia Market Unmet Needs
- Challenges in diagnosis
- Development of novel therapies
- Limitations in gene therapy
- Poor disease understanding
- Clinical biomarkers
Scope of the Friedreich’s Ataxia Market Report
- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Friedreich’s Ataxia Companies: Reata Pharmaceuticals, Retrotope, PTC Therapeutics, Minoryx Therapeutics, and others
- Key Friedreich’s Ataxia Therapies: Omaveloxolone, RT001, Vatiquinone, Leriglitazone, and others
- Friedreich’s Ataxia Therapeutic Assessment: Friedreich’s Ataxia current marketed and Friedreich’s Ataxia emerging therapies
- Friedreich’s Ataxia Market Dynamics: Friedreich’s Ataxia market drivers and Friedreich’s Ataxia market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Friedreich’s Ataxia Unmet Needs, KOL’s views, Analyst’s views, Friedreich’s Ataxia Market Access and Reimbursement
Discover more about therapies set to grab major Friedreich’s Ataxia market share @ Friedreich’s Ataxia market forecast
Table of Contents
1. Friedreich’s Ataxia Market Report Introduction
2. Executive Summary for Friedreich’s Ataxia
3. SWOT analysis of Friedreich’s Ataxia
4. Friedreich’s Ataxia Patient Share (%) Overview at a Glance
5. Friedreich’s Ataxia Market Overview at a Glance
6. Friedreich’s Ataxia Disease Background and Overview
7. Friedreich’s Ataxia Epidemiology and Patient Population
8. Country-Specific Patient Population of Friedreich’s Ataxia
9. Friedreich’s Ataxia Current Treatment and Medical Practices
10. Friedreich’s Ataxia Unmet Needs
11. Friedreich’s Ataxia Emerging Therapies
12. Friedreich’s Ataxia Market Outlook
13. Country-Wise Friedreich’s Ataxia Market Analysis (2020–2034)
14. Friedreich’s Ataxia Market Access and Reimbursement of Therapies
15. Friedreich’s Ataxia Market Drivers
16. Friedreich’s Ataxia Market Barriers
17. Friedreich’s Ataxia Appendix
18. Friedreich’s Ataxia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/